Heron (HRTX) - שווי פעילות לרווח לפני ריבית, מסים ופחת
Heron Therapeutics (HRTX) is actively expanding its product portfolio through hospital supplies and non-opioid analgesics, moving away from a narrow specialization in supportive care. Simultaneously, the business is implementing sustainable water cycles and reducing its carbon footprint in logistics. The current EV/EBITDA multiple is 0.00. The company's price chart demonstrates its leadership position in the segment of extended-release anti-nausea and pain medications, protected by a unique polymer delivery system.
HRTX (Heron): פילוחים אנליטיים ודוחות לפי אינדיקטורים
The multiple compares the total enterprise value (assets plus debt minus cash) with operating profit before taxes and depreciation. This ratio measures the speed of capital payback, reacting sensitively to borrowing costs and operating expenses. For Heron Therapeutics (HRTX), this calculation is critical during the transition from losses to drug monetization and cost optimization. The trend of the EV/EBITDA multiple for this capital-intensive enterprise determines the current investment attractiveness of the company.
